verapamil has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 8 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 6.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 5.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 2.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 1.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biscardi, M | 1 |
| Teodori, E | 1 |
| Caporale, R | 1 |
| Budriesi, R | 1 |
| Balestri, F | 1 |
| Scappini, B | 1 |
| Gavazzi, S | 1 |
| Grossi, A | 1 |
| Wilson, WH | 2 |
| Bates, SE | 2 |
| Fojo, A | 1 |
| Bryant, G | 1 |
| Zhan, Z | 2 |
| Regis, J | 2 |
| Wittes, RE | 1 |
| Jaffe, ES | 1 |
| Steinberg, SM | 1 |
| Herdt, J | 1 |
| Tidefelt, U | 1 |
| Juliusson, G | 1 |
| Elmhorn-Rosenborg, A | 1 |
| Peterson, C | 2 |
| Paul, C | 1 |
| Fojo, AT | 1 |
| Alvarez, M | 1 |
| Robey, R | 1 |
| Hose, C | 1 |
| Monks, A | 1 |
| Kang, YK | 1 |
| Chabner, B | 1 |
| Gaynor, ER | 1 |
| Unger, JM | 1 |
| Miller, TP | 2 |
| Grogan, TM | 2 |
| White, LA | 1 |
| Mills, GM | 1 |
| Balcerzak, SP | 1 |
| Varterasian, M | 1 |
| LeBlanc, M | 1 |
| Fisher, RI | 1 |
| Laine, K | 1 |
| Valavaara, R | 1 |
| Rouru, J | 1 |
| Dalton, WS | 1 |
| Meltzer, PS | 1 |
| Scheper, RJ | 1 |
| Durie, BG | 1 |
| Taylor, CW | 1 |
| Salmon, SE | 1 |
| Reizenstein, P | 1 |
| Kapoor, R | 1 |
| Gruber, A | 1 |
1 review available for verapamil and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1996 |
2 trials available for verapamil and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2001 |
5 other studies available for verapamil and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Aorta; | 2006 |
Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Doxorubicin; Drug Interactions; | 1994 |
[Drug interaction behind the toxicity of chemotherapy].
Topics: Aged; Anti-Arrhythmia Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; C | 1998 |
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter | 1989 |
Accumulation of vincristine and doxorubicin in malignant lymphocytes with different immunophenotypes.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; B-Lymphocytes; Doxorubicin; Female; Fluorescent Ant | 1989 |